Objectives: CLL disease pathophysiology and BTK inhibitors efficacy data.

Objectives: Pre-treatment patient assessment and Treatment selection and patient monitoring

Objectives: How to avoid premature treatment discontinuation of IMBRUVICA and other BTKi?

Objectives: When to start you relapsed refractory therapy?

Objectives: Is there a place for BMT in CLL? Real cases: Is it a CLL progression....